Abstract: The present invention relates to inhibitors of GSK-3 and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors and methods of utilizing those compositions in the treatment and prevention of various disorders, such as diabetes and Alzheimer's disease. In addition, the invention relates to molecules or molecular complexes which comprise binding pockets of GSK-3? or its homologues. The invention relates to a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. The invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. The invention relates to methods of using the structure coordinates to screen for and design compounds that bind to GSK-3? protein or homologues thereof. The invention also relates to crystallizable compositions and crystals comprising GSK-3? protein or GSK-3? protein complexes.

Abstract: The present invention relates to inhibitors of GSK-3 and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors and methods of utilizing those compositions in the treatment and prevention of various disorders, such as diabetes and Alzheimer's disease. In addition, the invention relates to molecules or molecular complexes which comprise binding pockets of GSK-3? or its homologues. The invention relates to a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. The invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. The invention relates to methods of using the structure coordinates to screen for and design compounds that bind to GSK-3? protein or homologues thereof. The invention also relates to crystallizable compositions and crystals comprising GSK-3? protein or GSK-3? protein complexes.

Abstract: The present invention relates to inhibitors of GSK-3 and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors and methods of utilizing those compositions in the treatment and prevention of various disorders, such as diabetes and Alzheimer's disease. In addition, the invention relates to molecules or molecular complexes which comprise binding pockets of GSK-3? or its homologues. The invention relates to a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. The invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. The invention relates to methods of using the structure coordinates to screen for and design compounds that bind to GSK-3? protein or homologues thereof. The invention also relates to crystallizable compositions and crystals comprising GSK-3? protein or GSK-3? protein complexes.

Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the compounds and methods of using the compositions in the treatment of various disorders.

Abstract: The present invention relates to compounds of formula I that are useful as GSK-3 inhibitors. The invention also relates to methods of using compounds of formula I or pharmaceutical compositions comprising compounds of formula I to inhibit GSK-3 activity. The invention further provides methods of utilizing these compounds and pharmaceutical compositions in the treatment and prevention of various disorders, such as diabetes and Alzheimer's disease. The invention also relates to methods for inhibiting Aurora-2 activity and for treating or preventing Aurora-2-mediated diseases using compounds of formula I or pharmaceutical compositions comprising compounds of formula I. The invention also relates to methods for inhibiting cyclin-dependent kinase-2 activity and for treating or preventing inhibiting cyclin-dependent kinase-2-mediated diseases using compounds of formula I or pharmaceutical compositions comprising compounds of formula I.

Abstract: The present invention relates to inhibitors of GSK-3 and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors and methods of utilizing those compositions in the treatment and prevention of various disorders, such as diabetes and Alzheimer's disease. In addition, the invention relates to molecules or molecular complexes which comprise binding pockets of GSK-3? or its homologues. The invention relates to a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. The invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. The invention relates to methods of using the structure coordinates to screen for and design compounds that bind to GSK-3? protein or homologues thereof. The invention also relates to crystallizable compositions and crystals comprising GSK-3? protein or GSK-3? protein complexes.

Abstract: The present invention relates to inhibitors of GSK-3 and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors and methods of utilizing those compositions in the treatment and prevention of various disorders, such as diabetes and Alzheimer's disease. In addition, the invention relates to molecules or molecular complexes which comprise binding pockets of GSK-3? or its homologues. The invention relates to a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. The invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. The invention relates to methods of using the structure coordinates to screen for and design compounds that bind to GSK-3? protein or homologues thereof. The invention also relates to crystallizable compositions and crystals comprising GSK-3? protein or GSK-3? protein complexes.

Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the compounds and methods of using the compositions in the treatment of various disorders.

Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the compounds and methods of using the compositions in the treatment of various disorders.

Abstract: The present invention relates to compounds of formula I that are useful as GSK-3 inhibitors. The invention also relates to methods of using compounds of formula I or pharmaceutical compositions comprising compounds of formula I to inhibit GSK-3 activity. The invention further provides methods of utilizing these compounds and pharmaceutical compositions in the treatment and prevention of various disorders, such as diabetes and Alzheimer's disease. The invention also relates to methods for inhibiting Aurora-2 activity and for treating or preventing Aurora-2-mediated diseases using compounds of formula I or pharmaceutical compositions comprising compounds of formula I. The invention also relates to methods for inhibiting cyclin-dependent kinase-2 activity and for treating or preventing inhibiting cyclin-dependent kinase-2-mediated diseases using compounds of formula I or pharmaceutical compositions comprising compounds of formula I.

Abstract: The present invention relates to compounds of formula I that are useful as GSK-3 inhibitors. The invention also relates to methods of using compounds of formula I or pharmaceutical compositions comprising compounds of formula I to inhibit GSK-3 activity. The invention further provides methods of utilizing these compounds and pharmaceutical compositions in the treatment and prevention of various disorders, such as diabetes and Alzheimer's disease. The invention also relates to methods for inhibiting Aurora-2 activity and for treating or preventing Aurora-2-mediated diseases using compounds of formula I or pharmaceutical compositions comprising compounds of formula I. The invention also relates to methods for inhibiting cyclin-dependent kinase-2 activity and for treating or preventing inhibiting cyclin-dependent kinase-2-mediated diseases using compounds of formula I or pharmaceutical compositions comprising compounds of formula I.

Abstract: The present invention relates to inhibitors of GSK-3 and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors and methods of utilizing those compositions in the treatment and prevention of various disorders, such as diabetes and Alzheimer's disease. In addition, the invention relates to molecules or molecular complexes which comprise binding pockets of GSK-3&bgr; or its homologues. The invention relates to a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. The invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. The invention relates to methods of using the structure coordinates to screen for and design compounds that bind to GSK-3&bgr; protein or homologues thereof. The invention also relates to crystallizable compositions and crystals comprising GSK-3&bgr; protein or GSK-3&bgr; protein complexes.

Abstract: There is described a thermal recording system which utilizes a donor element comprising a substrate and a thermal transfer material layer having a dye-containing phase which is amorphous and wherein the dye or dyes present in the amorphous phase form a continuous film. Imagewise heating of the medium transfers portions of the transfer layer to a receiver sheet, thus forming an image. The transfer layer may also include a non-dye phase comprising a thermal solvent. During the heating of the donor element, the crystalline thermal solvent melts and dissolves or liquefies at least a portion of the dye-containing phase, thereby lowering the temperature at which transfer of the transfer layer occurs.

Abstract: There is described a thermal recording system which utilizes a donor element comprising a substrate and a thermal transfer material layer having a dye-containing phase which is amorphous and wherein the dye or dyes present in the amorphous phase form a continuous film. Imagewise heating of the medium transfers portions of the transfer layer to a receiver sheet, thus forming an image. The transfer layer may also include a non-dye phase comprising a thermal solvent. During the heating of the donor element, the crystalline thermal solvent melts and dissolves or liquefies at least a portion of the dye-containing phase, thereby lowering the temperature at which transfer of the transfer layer occurs.

Abstract: There are described image-recording materials which include an image dye-providing compound comprising a novel naphthol azo cyan dye having a 3-aminobenzoisothiazole moiety. The image dye-providing compound includes a diffusion control moiety such as a hydroquinonyl developer group, a precursor thereof or a thiazolidine moiety and, may be diffusible or nondiffusible as a function of the diffusion control moiety.Image-recording materials according to the invention including those which contain high potential developers such as aminoreductone allow sufficient cyan chromophore to diffuse to the image-receiving layer to provide an acceptable photograph and result in no appreciable reduction of the 3-aminobenzoisothiazole moiety of the novel naphthol azo cyan dye.

Abstract: There are described image-recording materials which include an image dye-providing compound comprising a novel naphthol azo cyan dye having a 3-aminobenzoisothiazole moiety. The image dye-providing compound includes a diffusion control moiety such as a hydroquinonyl developer group, a precursor thereof or a thiazolidine moiety and, may be diffusible or nondiffusible as a function of the diffusion control moiety.Image-recording materials according to the invention including those which contain high potential developers such as aminoreductone allow sufficient cyan chromophore to diffuse to the image-receiving layer to provide an acceptable photograph and result in no appreciable reduction of the 3-aminobenzoisothiazole moiety of the novel naphthol azo cyan dye.

Abstract: There are described compounds which are represented by the formula ##STR1## The compounds are useful as dyes, and as intermediates and dye moieties in the preparation of compounds, which are particularly useful in imaging applications, such as, for example, diffusion transfer photographic systems.

Abstract: There are disclosed color-providing compounds comprising two or more cyclic 1,3 sulfur-nitrogen groups and two or more color-providing moieties, i.e., complete dyes or dye intermediates, capable of releasing the color-forming moieties upon cleavage in the presence of silver ions or a soluble silver complex. The color-providing compounds are useful as image-forming materials in color photographic processes.

Abstract: There are disclosed compounds comprising at least one cyclic 1,3-sulfur-nitrogen substituted color-providing material and at least one ballast group which are linked to each other through a triazine group. The compounds are capable of releasing the color-providing material upon cleavage in the presence of silver ions or a soluble silver complex. The color-providing compounds are useful as image-forming materials in color thermographic, photothermographic and other photographic processes.

Abstract: There are disclosed color-providing compounds comprising two or more cyclic 1,3 sulfur-nitrogen groups and two or more color-providing moieties, i.e., complete dyes or dye intermediates, capable of releasing the color-forming moieties upon cleavage in the presence of silver ions or a soluble silver complex. The color-providing compounds are useful as image-forming materials in color photographic processes.